A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
Nxera Pharma UK Limited · Healthy
Phase 1
Completed
42
2025-02
Industry sponsor intelligence
Nxera Pharma UK LimitedClinical Pipeline.
Lead-sponsor view of Nxera Pharma UK Limited's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 42
Pipeline overview
Programs by phase and activity.
Velocity
Nxera Pharma UK Limited trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 11
Phase 20
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Desmopressin → | 1 | 1 | 0 | 0 | 0 | 0 |
| Pasireotide → | 1 | 1 | 0 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All Nxera Pharma UK Limited studies.
This page groups studies where Nxera Pharma UK Limited is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates